PreMD Reports Second Quarter 2007 Results

    TORONTO, Aug. 14 /CNW/ - Predictive medicine company PreMD Inc.
(TSX: PMD; Amex:   PME) today announced results for the second quarter of fiscal
2007 ended June 30, 2007 ("Q2 2007").

    Recent Significant Highlights
    -   Completed a U.S. marketing and distribution partnership with
        AstraZeneca Pharmaceuticals for PREVU(*).
    -   Submitted a 510(k) application to U.S. Food and Drug Administration
        (FDA) for an expanded regulatory claim for PREVU(*) POC.
    -   Completed a manufacturing and supply agreement with Fisher
        Diagnostics (a subsidiary of ThermoFisher Scientific) for the
        manufacturing and assembly of PREVU(*) POC test kits and PREVU(*) LT
    -   The American Stock Exchange accepted continued listing plan.
    -   Received Notice of Allowance for a United States patent on PREVU(*)
        LT from United States Patent and Trademark Office (USPTO).
    -   Granted approval by the Canadian Intellectual Property Office for two
        patents titled: 'Screening Test for Early Detection of Colorectal
        Cancer' and 'Screening Test for Early Detection of Colorectal
    -   Awarded registered trademarks for the name 'PreMD' as well as the
        corporate slogan 'Predict to Prevent' by the Canadian Intellectual
        Property Office.
    -   Completed two scientific submissions based on findings from PREPARE
        and PASA studies.
    -   Acceptance of PASA abstract for presentation at the American Heart
        Association Scientific Sessions 2007.

    "Last Fall we outlined several significant company milestones that we
wanted to achieve during 2007. We are pleased with the progress we have made
to date, especially with the recent announcements regarding our agreement with
AstraZeneca, our submission to the FDA for an expanded regulatory claim for
PREVU(*) POC, and our recent acceptance of our PASA abstract by the American
Heart Association," said Brent Norton, president and chief executive officer
of PreMD. "Signing an agreement with AstraZeneca for the marketing and
distribution of PREVU(*) in the U.S. is an important milestone and we are
confident that they are the right partner for the product. It is anticipated
that PREVU(*) will be partnered for distribution within other territories in
2007 as well. Our business development efforts are also focused on other
products in our pipeline, specifically seeking potential partnerships for our
PREVU(*) LT test to the life-insurance industry and our line of oncology
products. In the interim, we anticipate hearing from the FDA regarding our
510 (k) application for PREVU(*) POC, which will strengthen the value of
    "In signing a manufacturing and supply agreement with Fisher Diagnostics,
we believe that their expertise could greatly benefit our strategic product
initiatives. Through extensive industry research, we determined that they were
best suited to address PreMD's impending growing supply chain needs, driven by
our recent partnership with AstraZeneca and anticipated partnerships with
other organizations. Also, Fisher Diagnostics is a leading organization that
currently supplies several of the world's leading medical companies."
    Dr. Norton continued, "As we look to continually expand our product
platform, our newly allowed patents provide broad protection to our colorectal
cancer screening portfolio and enhance the value of the company's intellectual
property. We continue to initiate and execute clinical trials in our targeted
areas, thereby building a strong foundation for our future in predictive
medicine. We look forward to reporting the achievement of additional
milestones during the remainder of 2007."

    Financial Review
    The consolidated net loss for the three months ended Q2 2007 was
$1,341,000 or $(0.05) per share compared with a loss of $2,115,000 or $(0.10)
per share for the quarter ended Q2 2006, primarily due to a decrease in
clinical trial expenses and unrealized foreign exchange gains on the
revaluation of the convertible debentures.
    Total product sales were $8,000 for Q2 2007 compared with $5,000 for Q2
2006. License revenue was nil for Q2 2007, compared to $80,000 for Q2 2006.
    During Q2 2007, the Company focused on managing the cancer clinical trial
program and on preparing the submission to the FDA requesting an expanded
claim for PREVU(*) POC. Most of the skin cholesterol clinical trials were
completed at the end of 2006. As a result, research and development
expenditures for the quarter decreased by $739,000 to $731,000 from $1,470,000
in Q2 2006. The variance for the period reflects:

    -   a decrease of $686,000 in spending on clinical trials for PREVU(*),
        following the completion of most of the trials;
    -   a decrease of $152,000 in spending on the cancer clinical trials;
    -   an increase of $95,000 on product development in support of
        manufacturing validation for the new cordless reader and for general
        product improvements; and
    -   a decrease of $15,000 in legal fees on intellectual property.

    General and administration expenses amounted to $911,000 for Q2 2007
compared with $689,000 in Q2 2006, an increase of $222,000. The increase for
the quarter includes:

    -   a decrease in stock-based compensation, a non-cash expense, of
        $51,000 to $123,000 for Q2 2007 compared with $174,000 for Q2 2006;
    -   an increase of $239,000 in professional fees for legal, audit and
        consulting related to business development; and
    -   an increase of $46,000 in expenses related to investor

    Interest on convertible debentures (issued on August 30, 2005) amounted
to $165,000 in Q2 2007 compared with $173,000 in Q2 2006. The debentures bear
interest at an annual rate of 7%, payable quarterly in either cash or stock.
Imputed interest of $255,000 and $173,000 in Q2 2007 and 2006 respectively,
represents the expense related to the accretion of the liability component, at
an effective interest rate of 14.8% (12.75% in 2006), effective January 1,
2007. Amortization of the deferred financing fees is included in imputed
interest whereas it was included in amortization expenses in 2006.
    Amortization expenses for capital assets and intangible assets for Q2
2007 amounted to $41,000 compared with $110,000 for Q2 2006.
    The gain on foreign exchange was $671,000 for Q2 2007, compared with a
gain of $278,000 for Q2 2006. The major contributing factor for the increase
was the impact of foreign exchange rates on the convertible debentures which
are repayable in U.S. dollars.
    Interest income amounted to $37,000 for Q2 2007 compared with $70,000 for
Q2 2006 as a result of lower cash balances. Refundable scientific investment
tax credits ("ITCs") accrued for Q2 2007 amounted to $26,000 versus $70,000
for Q2 2006. This decrease was due to the reduced spending on clinical trials
in 2007.
    Accounts payable at June 30, 2007 amounted to $352,000 compared with
$964,000 at December 31, 2006. The large decrease resulted from the payment of
expenses related to clinical trials that were completed near the end of 2006.
    As at June 30, 2007, PreMD had cash, cash equivalents and short-term
investments totaling $3,539,000 ($3,276,000 as at December 31, 2006). The
Company invests its funds in short-term financial instruments and marketable
securities. Cash used to fund operating activities during Q2 2007 amounted to
$1,264,000 compared with $1,835,000 in Q2 2006.
    To date, the Company has financed its activities through product sales,
license revenues, the issuance of shares and convertible debentures and the
recovery of investment tax credits (ITCs). Management believes that, based on
our reduced cash expenditures and the current expectation of further revenues
from product sales, royalties and license revenues, its existing cash
resources together with the proceeds of the private placement on March 27,
2007 and the ITC receivable of $248,000 will be sufficient to meet its current
operating and capital requirements.

    About PreMD Inc.

    PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products are branded as PREVU(*) Skin
Cholesterol Test, to be marketed and distributed by AstraZeneca. The company's
cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer
test. PreMD's head office is located in Toronto, Ontario and its research and
product development facility is at McMaster University in Hamilton, Ontario.
For further information, please visit For more information
about PREVU(*), please visit

    This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the success of a plan for regaining compliance with certain continued
listing standards of the American Stock Exchange, successful development or
marketing of the Company's products, the competitiveness of the Company's
products if successfully commercialized, the lack of operating profit and
availability of funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, product liability, reliance on
third-party manufacturers, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory process, and
general changes in economic conditions.
    In addition, while the Company routinely obtains patents for its products
and technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.
    Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.


                               (Tables Follow)

    PreMD Inc.
    Incorporated under the laws of Canada

                         CONSOLIDATED BALANCE SHEETS
                            (In Canadian dollars)

                                                       As at        As at
                                                      June 30,   December 31,
                                                        2007         2006
                                                          $            $

    Cash and cash equivalents                         2,515,438      112,577
    Short-term investments                            1,023,987    3,163,482
    Accounts receivable                                   8,443       11,221
    Inventory                                           178,004      179,219
    Prepaid expenses and other receivables              537,650      570,773
    Investment tax credits receivable                   248,000      200,000
    Total current assets                              4,511,522    4,237,272
    Deferred financing fees, net of accumulated
     amortization of $174,863 in 2006                         -      347,589
    Capital assets, net of accumulated amortization
    of $883,699 (2006 - $841,611)                       268,589      312,410
    Intangible assets, net of accumulated
     amortization of $953,250 (2006 - $915,027)         344,007      382,229
                                                      5,124,118    5,279,500

    Accounts payable                                    352,106      963,990
    Accrued liabilities                                 716,590      932,372
    Total current liabilities                         1,068,696    1,896,362
    Convertible debentures                            5,704,665    6,350,680
    Total liabilities                                 6,773,361    8,247,042

    Shareholders' deficiency
    Capital stock                                    28,883,949   25,263,480
    Contributed surplus                               2,758,169    2,521,915
    Equity component of convertible debentures        2,239,385    2,239,385
    Warrants                                          1,562,154    1,170,020
    Deficit                                         (37,092,900) (34,162,342)
    Total shareholders' deficiency                   (1,649,243)  (2,967,542)
                                                      5,124,118    5,279,500

    PreMD Inc.

                            (In Canadian dollars)

                             Three months ended          Six Months Ended
                                   June 30                   June 30
                          ------------------------- -------------------------
                              2007         2006         2007         2006
                                $            $            $            $

    Product sales               8,250        5,015       26,334        5,132
    License revenue                 -       79,624            -      156,675
                                8,250       84,639       26,334      161,807
    Cost of product sales       3,720        4,255        8,566        4,383
    Gross Profit                4,530       80,384       17,768      157,424

    Research and development  730,799    1,469,815    1,371,636    2,985,524
    General and
     administration           911,141      688,617    1,552,105    1,265,865
    Interest on convertible
     debentures               165,400      172,623      328,983      338,137
    Imputed interest on
     convertible debentures   231,228      172,720      479,574      404,132
    Amortization               41,318      110,110       82,698      154,932
    Gain on foreign exchange (670,888)    (227,675)    (754,441)    (215,043)
                            1,408,998    2,336,210    3,060,555    4,933,547

    Investment tax credits     26,000       70,000       48,000      130,000
    Interest                   37,105       70,394       64,229      156,929
                               63,105      140,394      112,229      286,929
    Net loss for
     the period            (1,341,363)  (2,115,432)  (2,930,558)  (4,489,194)
    Deficit, beginning
     of period            (35,751,537) (30,587,133) (34,162,342) (28,213,371)
    Deficit, end
     of period            (37,092,900) (32,702,565) (37,092,900) (32,702,565)

    Basic and diluted
     loss per share            $(0.05)      $(0.10)      $(0.12)      $(0.21)

    Weighted average
     number of common
     shares outstanding    24,950,579   21,566,994   23,505,688   21,559,121

    PreMD Inc.

                            (In Canadian dollars)

                             Three months ended          Six Months Ended
                                   June 30                   June 30
                          ------------------------- -------------------------
                              2007         2006         2007         2006
                                $            $            $            $
    Net loss for
     the period            (1,341,363)  (2,115,432)  (2,930,558)  (4,489,194)
    Add items not
     involving cash
      Amortization             41,318      110,110       82,698      154,932
      Stock compensation
       costs included in:
        Research and
         development expense   35,286       58,904       67,383       94,719
        General and
         expense              123,312      173,741      180,605      243,212
      Gain on sale of
       capital asset              143            -          143            -
      Imputed interest
       on convertible
       debentures             231,228      172,720      479,574      404,132
      Interest on
       debentures paid
       in common shares       133,967       79,702      270,911       79,702
      Deduct gain on
       foreign exchange      (670,888)    (277,675)    (754,441)    (215,043)
    Net change in non-cash
     working capital
      Balances related
       to operations          182,749       44,745     (838,718)   1,296,533

    Decrease in deferred
     revenue                        -      (81,867)           -     (158,592)
    Cash used in operating
     activities            (1,264,248)  (1,835,052)  (3,442,403)  (2,589,599)

    Short-term investments    291,768    1,695,094    2,109,459    1,881,904

    Sale of capital assets        562            -        1,435            -
    Purchase of capital assets   (484)      (2,817)      (2,233)     (20,915)
    Cash provided by
     investing activities     291,846    1,692,277    2,108,661    1,860,989

    Issuance of capital
     stock, net of issue
     costs                    (49,764)           -    3,729,957            -
    Cash provided by
     financing activities     (49,764)           -    3,729,957            -
    Effect of exchange rate
     changes on cash and
     cash equivalents           3,870        4,145        6,646       46,212
    Net increase (decrease)
     in cash and cash
     equivalents during
     the period            (1,018,296)    (138,630)   2,402,861     (682,398)
    Cash and cash
     - Beginning of period  3,533,734      229,431      112,577      773,199
     - End of period        2,515,438       90,801    2,515,438       90,801

    Represented by
    Cash                      105,372       90,801      105,372       90,801

    Cash equivalents        2,410,066            -    2,410,066            -

                            2,515,438       90,801    2,515,438       90,801

    %SEDAR: 00007927E          %CIK: 0001179083

For further information:

For further information: Brent Norton, President and CEO, Tel: (416)
222-3449 ext. 22, Email:; Ron Hosking, Vice President
Finance and CFO, Tel: (416) 222-3449 ext. 24, Email:;
Michelle Rabba, Manager, Corporate Communications, Tel: (416) 222-3449 ext.
25, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890